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Department of Pain Medicine, Division of Anesthesiology and Critical Care, The University of Texas MD Anderson Cancer
Center, Houston, TX, USA
Chemotherapy-induced neuropathic pain is difficult to treat and prevent. Tempol
decreases cellular superoxide radical levels and oxidative stress. The aims of our
study were to investigate the analgesic and preventive effects of tempol on paclitaxel-
induced neuropathic pain in rats and to identify the associated mechanisms of action.
Neuropathic pain was induced with intraperitoneally injected paclitaxel on four alternate
days in male Sprague–Dawley rats. Tempol was administered systemically as a single
injection and a continuous infusion before or after the injection of paclitaxel. The
mechanical threshold for allodynia, protein levels, and free radical levels were measured
using von Frey filaments, Western blotting, and live cell imaging, respectively. After
the rats developed neuropathic pain behavior, a single intraperitoneal injection and
continuous infusion of tempol ameliorated paclitaxel-induced mechanical allodynia.
Systemic infusion of tempol in the early phase of the development of pain behavior
prevented the development of paclitaxel-induced pain behavior. Paclitaxel increased
the levels of phosphorylated protein kinase C, phosphorylated nuclear factor κB,
phosphodiesterase 4D (PDE4D), IL-1β, and monocyte chemoattractant protein-1 in
the lumbar dorsal root ganglia; however, tempol decreased these levels. Paclitaxel also
increased superoxide levels in a culture of primary dorsal root ganglion cells and tempol
decreased these levels. In conclusion, tempol alleviates and prevents chemotherapy-
induced neuropathic pain in rats by reducing the levels of inflammatory cytokines and
free radicals in dorsal root ganglia.
Keywords: chemotherapy, neuropathic pain, free radical, inflammatory cytokines, paclitaxel, tempol
INTRODUCTION
Chemotherapeutic agents, including taxanes (e.g., paclitaxel, docetaxel), vinca alkaloids (e.g.,
vincristine, vinblastine), platinum agents (e.g., cisplatin, carboplatin, oxaliplatin), and others (e.g.,
thalidomide, bortezomib, lenalidomide), produce peripheral pain in the distal extremities in a
symmetrical glove and stocking distribution (Yazdani and Abdi, 2014). Chemotherapy-induced
neuropathic pain is a dose-limiting adverse effect that can take place at any time during the course
of the treatment or even after its termination (Windebank and Grisold, 2008). This neuropathy
can significantly decrease the overall quality of life in cancer patients (Mols et al., 2014; Rivera and
Cianfrocca, 2015).
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To date, analgesic drugs such as opioids, non-steroidal
anti-inflammatory agents, anticonvulsants, antidepressants, and
sodium channel blockers show little or no analgesic effects in
paclitaxel-induced neuropathic pain (PINP) models (Xiao et al.,
2008). It has also been reported that glutamine, glutathione,
N-acetylcysteine, oxcarbazepine, and xaliproden did not prevent
chemotherapy-induced neuropathy (Wolf et al., 2008). On
the other hand, there have been several preclinical reports
indicating cannabinoids might have some effects in reducing
chemotherapy-induced peripheral neuropathy (Deng et al., 2012,
2015; Khasabova et al., 2012; Guindon et al., 2013; Vera et al.,
2013; Harris et al., 2016), but their clinical efficacy has not
been proved yet. Therefore, currently, no effective medications
are available to treat or prevent neuropathic pain (Lee and
Swain, 2006; Wolf et al., 2008; Hershman et al., 2014) and new
alternatives need to be explored.
Several pain models have shown that systemic or spinal
administration of free radical scavengers, including phenyl
N-tert-butylnitrone and vitamin E, reduce pain behavior (Kim
et al., 2004, 2006). In addition, tempol, a membrane-permeable
superoxide dismutase mimetic, was reported to attenuate
zymosan-induced visceral pain behavior and peroxynitrite-
enhanced carrageenan-induced hyperalgesia (Khattab, 2006; Ji
et al., 2015). Tempol is a member of nitroxide compounds and
reacts with superoxide anion to form hydrogen peroxide. In
addition, the sensitivity of tempol was greatest for hydroxyl
radical, intermediate for hydrogen peroxide, and least for
superoxide radical (Soule et al., 2007; Wilcox and Pearlman,
2008). The toxic doses of tempol are about 172.25–344.5 mg/kg
when animals were intraperitoneally injected (Hahn et al., 1998).
Tempol reduced oxidative damage in cerebral synaptosomes
from gerbils and reduced exacerbated hypoxic brain damage
(Howard et al., 1996; MacGregor et al., 2003). Tempol blocked
the enhanced N-methyl-D-aspartate-induced neurotoxicity in
cultured cortical brain cells (Hewett et al., 1994; Teichner
et al., 2003). In addition, several studies have reported that
tempol reduced tumor growth and incidence of cancer. Tempol
decreased glioma formation in rats and delayed the development
of tumors, and prolonged the lifespan of cancer-prone mice
(Gariboldi et al., 2003; Erker et al., 2005; Zhang et al., 2008).
However, the analgesic and preventive effects of tempol on
chemotherapy-induced neuropathic pain have not been studied.
The aims of this study were to investigate (1) the analgesic effects
of tempol on PINP in rats, (2) the preventive effects of tempol
on the development of PINP in rats, and (3) the mechanisms of
action of tempol in the dorsal root ganglia (DRGs).
MATERIALS AND METHODS
Experimental Animals
Male adult Sprague–Dawley rats (200–350 g; Harlan Sprague–
Dawley Company, Houston, TX, USA) were used for the
experiment. They had free access to food and water and were
housed in a room with a normal light-dark cycle (light cycle: 7:00
a.m. to 7:00 p.m.). All animals were habituated for 1 week before
the experiments. The experimental protocol was approved by the
institutional animal care and use committees of The University of
Texas MD Anderson Cancer Center.
Paclitaxel-Induced Neuropathic Pain
Paclitaxel (Sigma, St. Louis, MO, USA) was dissolved in a vehicle
solution (4% dimethyl sulfoxide and 4% Tween 80 in sterile
saline) and was injected intraperitoneally at a dose of 2 mg/kg
on days 0, 2, 4, and 6 (Polomano et al., 2001; Kim et al., 2010).
Control rats were injected with the same volume of vehicle
without paclitaxel.
Measurement of Mechanical Allodynia
To measure mechanical allodynia, we used a behavior test that
has been described previously (Chaplan et al., 1994). Briefly, rats
were placed in a plastic chamber on top of a mesh screen, and
the mechanical threshold of the left hind paw was determined
by the up-down method (Dixon, 1980) using monofilaments
(0.45–14.45 g). A filament was applied to the most sensitive parts
of the paw’s plantar surface – the center of the paw or the base
of the third or fourth toes – for 3–4 s. A sudden withdrawal
of the foot during stimulation or immediately after removal of
the filament was considered to be a positive response. A 50%
mechanical threshold value was calculated. The investigator who
conducted the behavioral tests was blinded to the control or
treatment status of the rats.
Western Blot Analysis
The rats were anesthetized deeply with 4% isoflurane for
induction for 5 min and then 3% for the maintenance. During
anesthesia, rats were removed hair, opened chest cavity, and
then perfused with cold saline. The L1-6 DRGs were removed,
frozen in liquid nitrogen, and then stored in deep freezer
(−80◦C). They were homogenized in 150 µl of RIPA cell
lysis buffer with a protease inhibitor on ice by homogenizer
four times for 20 s (interval time: 2 min) and centrifuged
at 17,000 × g at 4◦C for 10 min. And then supernatants
were loaded in 10% sodium dodecyl sulfate-polyacrylamide
gels and transferred to polyvinylidene fluoride membranes.
Blots were incubated with primary antibody against IL-1β
(1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), MCP-1
(1:500; Santa Cruz Biotechnology, Dallas, TX, USA), PDE4D
(1:5000; Abcam, Cambridge, MA, USA), phosphorylated nuclear
factor κB (p-NF-κB, 1:1000; Cell Signaling Technology, Danvers,
MA, USA), phosphorylated protein kinase C (p-PKC, 1:1000;
Cell Signaling Technology, Danvers, MA, USA), and GAPDH
(1:5000; Santa Cruz Biotechnology, Dallas, TX, USA) overnight at
4◦C. The blots were then incubated with anti-rabbit horseradish
peroxidase-conjugated secondary antibody (1:5000; GenDepot,
Katy, TX, USA) or anti-goat horseradish peroxidase-conjugated
secondary antibody (1:5000; GenDepot, Katy, TX, USA). The
immunoblots were analyzed with a chemiluminescence detection
system and normalized to GAPDH. For equalizing protein
loading, GAPDH expression was used as a control.
Behavioral Testing for Sedation
Behavioral testing for sedation was based on five-point scales of
posture (0 = normal, 4 = flaccid atonia) and righting reflexes
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FIGURE 1 | Schematic overview of the experimental design. Note, N
represented single intraperitoneal injection of paclitaxel, ↑ represented single
intraperitoneal injection of tempol, and represented intraperitoneal
infusion of tempol.
(0= struggles, 4= no movement; Devor and Zalkind, 2001; Kim
et al., 2004). Sedation was assessed immediately after each pain
behavior test.
Administration of Tempol
This study consisted of two parts: (1) Assessment of the
therapeutic effects of tempol on PINP, given as a single
intraperitoneal injection (50, 100, or 200 mg/kg) or as
intraperitoneal infusion (10 mg/day for 7 days), and (2)
investigation of the preventive effects of tempol given
as intraperitoneal infusion on development of PINP
(Figures 1A–C).
Assessment of the Therapeutic Effects of Tempol
For administration of tempol as a single intraperitoneal injection,
on day 20 after the first paclitaxel injection, 24 rats were divided
into four groups. After the rats developed neuropathic pain
behavior, they were randomly assigned to one of three treatment
groups or a control group. Rats in the treatment groups (six rats
per group) received 50, 100, or 200 mg/kg tempol in 5 mL/kg
saline, and rats in the control group received a single 5-mL/kg
injection of saline (Figure 1C).
For administration of tempol as a systemic intraperitoneal
infusion (Figure 1C), on the 20th day after the first paclitaxel
injection, the rats that developed neuropathic pain behavior
were randomly assigned to either a treatment group (tempol,
six rats) or a control group (vehicle, five rats) before the
insertion of a mini-osmotic pump (Alzet model 2001; Alzet,
Cupertino, CA, USA). The rats in the treatment group
received an infusion of tempol at a rate of 1 µL/h for
7 days (10 mg/day). Additionally, loading doses of tempol
(200 mg/kg) were administered on days 20 and 21 after the
first paclitaxel injection. The rats in the control group received
equivalent volumes of saline via the pump and as loading doses
(5 mL/kg).
Assessment of the Preventive Effects of Tempol
Tempol (10 mg/day) was infused intraperitoneally (Alzet model
2001 mini-osmotic pump) by one of the following methods
of administration. In paradigm I, a bolus of tempol was
injected intraperitoneally at a dose of 200 mg/kg on days 0
and 1 and continuously infused intraperitoneally for 7 days
(days 0 through 6; Figure 1A). In paradigm II, the same dose of
tempol was given as a bolus on days 6 and 7, and continuous
infusion was administered on days 6 through 13 (Figure 1B).
Mechanical allodynia was measured on days 0, 2, 4, 6, 7, 9,
10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 24, 26, 30, 34, 37, and
40. We measured the animal’s body weight regularly after the
aforementioned behavioral tests. There was normal increase in
their body weight. Furthermore, while observing animals, we did
not notice any stress.
Intraperitoneal Implantation of the
Mini-Osmotic Pump
The mini-osmotic pump was implanted intraperitoneally
according to the manufacturer’s protocol. Briefly, a midline skin
and peritoneal wall incision was made in the lower abdomen
of rats that had received isoflurane anesthesia in oxygen. The
pump was filled with tempol or saline and inserted into the
peritoneal cavity. The musculoperitoneal layer was sutured with
silk sutures, and the skin incision was closed with wound clips.
Anesthesia was discontinued, and the animals were allowed to
recover from anesthesia.
DRG Cell Culture
Dorsal root ganglia cells were cultured as previously described
with slight modifications (Shetty et al., 2015). Briefly, under
general anesthesia with isoflurane, the lumbar DRGs from L1
to L6 were removed in sterile conditions. The DRGs were then
dissociated with 1.25 mg/mL collagenase (Sigma) twice for 1 h at
37◦C and mechanical dissociation. Cells were plated on a 35-mm
dish (Costar, Corning, NY, USA) coated with poly-L-lysine
and laminin in Dulbecco’s Modified Eagle’s Medium (DMEM)
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin,
and 4 mM glutamine for 5 days in CO2 incubator (5% CO2,
37◦C). DRG cells were plated in a chambered coverglass with
cover No. 1.5 borosilicate sterile (four well, Thermo Fisher
Scientific, Waltham, MA, USA) in a volume of 1 mL of DMEM
with 5% FBS for live cell microscopy studies. The cells were
stained with trypan blue, and viability was measured by a
Luna automated cell counter (Logos Biosystems, Annandale,
VA, USA).
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Live Cell Imaging for Mitochondrial
Superoxide Level
Dorsal root ganglia cells were plated in a chambered coverglass
with cover No. 1.5 borosilicate sterile (four well, Thermo Fisher
Scientific) in a volume of 1 mL of DMEM with 5% FBS. After 24 h
incubation, cells were stained with 5 µM MitoSOX (Molecular
Probes, Eugene, OR, USA) for 10 min, washed with DMEM
twice, and then treated for 2 h with 1 µM paclitaxel in vehicle
(0.025% dimethyl sulfoxide in DMEM). MitoSOX is a novel
fluorogenic dye and produces red fluorescence by superoxide
from only mitochondria in live cells. In addition, MitoSOX can
permeate live cells where it selectively targets mitochondria.
Red fluorescent intensity in living cells were measured using
a Zeiss LSM510 Meta laser scanning confocal system (Carl
Zeiss, Inc, Thornwood, NY, USA) in a box incubator (5% CO2,
37◦C, Reinach, Switzerland). Confocal scanning setting was used
at the lowest laser intensity to capture pixels in the range
of 0–255. The images were quantified using Volocity imaging
software (Improvision, Perkin Elmer, Waltham, MA, USA). The
fluorescent threshold was set at 50–255. Data represent the sum
of pixels in an image by the area that produced red fluorescence.
Statistical Analyses
Data were summarized as means with standard errors of the
means for the behavioral testing, Western blotting, and live cell
imaging. The data were analyzed using the GraphPad Prism 6
and two-way repeated-measures analyses of variance with one
repeated factor (time), followed by the Tukey post hoc test for
behavioral testing and the Mann–Whitney U test for Western
blotting and cell imaging. In all cases, P < 0.05 was considered
statistically significant.
RESULTS
Tempol Did Not Produce Sedation
All rats treated with single (50, 100, 200 mg/kg) or infusion
(10 mg/day) of tempol or vehicle had a score of 0 on both the
posture and righting reflex scales, indicating that tempol did not
produce sedation. Reviewer recommended to use positive control
such as diazepam to validate the sedation experiment. At this
time, we did not use positive control because we had reported
several publications using this method (Devor and Zalkind,
2001; Kim et al., 2004, 2006, 2010, 2015). In addition, all rats
treated with tempol without paclitaxel showed normal behavior
including no sedation, no pain behavior, and normal increase in
body weight.
Tempol Increased the Mechanical
Threshold of PINP
Single intraperitoneal injection of tempol at doses of 50, 100,
and 200 mg/kg on day 20 increased mechanical threshold in a
dose-dependent manner in rats (Figure 2A). Moreover, the 200-
mg dose significantly increased mechanical threshold from 0.9 to
9.7 g at 0.5 h after injection compared with the saline group, but
FIGURE 2 | Analgesic effects of a single systemic injection (A) or
systemic infusion (B) of tempol on paclitaxel-induced neuropathic pain (PINP)
in rats. Paclitaxel (PAC, 2 mg/kg) was injected intraperitoneally on four
alternate days (days 0, 2, 4, and 6), and the mechanical threshold was
measured. (A) On day 20 after the first paclitaxel injection, 24 rats were
divided into four groups, which received an intraperitoneal injection of saline or
50, 100, or 200 mg/kg of tempol (5 mL/kg). Note that the mechanical
threshold returned to more than 10 g of mechanical threshold (no pain
condition in rats) at 0.5 h after the injection of 200 mg/kg of tempol. (B) On
day 20 after the first paclitaxel injection, 11 rats were divided into two groups.
In the tempol group (N = 6), the rats received an intraperitoneal infusion of
tempol (10 mg/day) for 7 days (hatched box) in combination with
intraperitoneal injections of tempol (200 mg/kg) on days 20 and 21
(arrowheads). In the saline group (N = 5), the rats received saline (vehicle)
instead of tempol. The systemic infusion of tempol significantly increased the
mechanical threshold on day 21, and the threshold remained significantly
higher than the threshold in the control group for 8 days. The data are
expressed as means with standard errors of the means. The asterisks indicate
values that are significantly different (P < 0.05) from the corresponding values
for the saline group as determined by a two-way repeated-measures analysis
of variance with one repeated factor (time) followed by the Tukey post hoc
test.
the threshold returned to baseline at 2 h. We selected 50, 100, and
200 mg/kg based on our preliminary data.
To investigate the extended analgesic effects of tempol,
200 mg/kg was intraperitoneally injected on days 20 and 21, and
10 mg/day was intraperitoneally infused for 7 days (Figure 2B).
The control group received intraperitoneal injections and
infusion of saline. Mechanical threshold was measured each
morning. Tempol significantly increased the mechanical
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threshold over that of the saline group on day 21, and the
threshold remained significantly higher on day 27. These data
indicate that infusion of tempol produced a prolonged analgesic
effect without sedation.
Tempol Prevented the Development of
PINP
To examine its preventive effects, tempol (10 mg/day) was
infused intraperitoneally for 7 days beginning 1 h before the
first paclitaxel injection (day 0) in paradigm I or beginning on
day 6 in paradigm II. The early treatment (starting on day 0)
did not affect the development of pain behavior (Figure 3A). In
contrast, the treatment beginning on day 6 completely prevented
further development of pain behavior for 40 days in paradigm
II (Figure 3B). These data indicate that tempol prevented the
development of PINP when given during the development phase
of mechanical hyperalgesia.
Paclitaxel Increased the Levels of
p-PKC, p-NF-κB, PDE4D, IL-1β, and
MCP-1 in DRGs, and Tempol
Subsequently Decreased the Levels
To examine the levels of signaling molecules, paclitaxel (2 mg/kg
on days 0, 2, 4, and 6) or vehicle (4% dimethyl sulfoxide
and 4% Tween 80 in saline) was intraperitoneally injected, and
L1-6 DRGs were collected on day 20 after the first injection
of paclitaxel or vehicle for Western blot analysis. Paclitaxel
significantly increased the levels of p-PKC (1.9 times), p-NF-κB
(2.1 times), PDE4D (1.7 times), IL-1β (1.9 times), and MCP-
1 (2.2 times) in the DRGs compared to those in the vehicle
control group (Figures 4A–F). Subsequently, tempol was infused
for 7 days (days 14–20), and lumbar DRGs were removed on
day 20 for Western blot analysis. Tempol decreased the levels
of p-PKC, p-NF-κB, PDE4D, IL-1β, and MCP-1 in the DRGs of
paclitaxel-treated rats to the levels in the DRGs of vehicle-injected
rats (Figures 4A–F).
Paclitaxel Increased Mitochondrial
Superoxide Levels in DRG Cell Culture,
and Tempol Subsequently Decreased the
Levels
To examine the effects of paclitaxel and tempol on mitochondrial
superoxide levels, the L1-6 DRGs were removed from a normal
adult rat and DRG cells were cultured with the MitoSOX
dye in a CO2 incubator. The MitoSOX reagent produces red
fluorescence by mitochondrial superoxide but not by other
free radicals. Paclitaxel increased the MitoSOX-detected red
fluorescence intensity (Figures 5A–E). The 1 µM of paclitaxel
significantly increased the fluorescence intensity at 2 (126%) and
4 h (132%) compared with before the treatment with paclitaxel
(Figures 5A,D,E). These data indicate that paclitaxel increased
the mitochondrial superoxide levels in the primary DRG cell
culture. The DRG cells were alive at levels of 85–95% when
treated with 1 µM of paclitaxel, but treatment with 5 µM of
FIGURE 3 | Preventive effects of tempol on PINP in rats. Paclitaxel (PAC,
2 mg/kg) was injected intraperitoneally on four alternate days (days 0, 2, 4,
and 6), and the mechanical threshold was measured. (A) On the day of the
first paclitaxel injection, 12 rats were divided into two groups. The rats in the
tempol group (N = 6), received an intraperitoneal infusion of tempol
(10 mg/day) for 7 days (hatched box) and an intraperitoneal injection of tempol
(200 mg/kg) on days 0 and 1 (arrowheads) of the infusion period. The rats in
the saline group (N = 6) received equivalent amounts of saline. The systemic
infusion of tempol did not affect the development of PINP. (B) On the day of
the last paclitaxel injection, another 15 rats were divided into two groups. The
rats in the tempol group (N = 7) received an intraperitoneal infusion of tempol
(10 mg/day) for 7 days (hatched box) and intraperitoneal injections of tempol
(200 mg/kg) on days 6 and 7 (arrowheads). The rats in the saline group
(N = 8) received equivalent volume of saline. The systemic infusion of tempol
significantly prevented the development of PINP. The data represent means
with standard errors of the means. The asterisks indicate values that are
significantly different (P < 0.05) from the corresponding values for the saline
group as determined by a two-way repeated-measures analysis of variance
with one repeated factor (time) followed by the Tukey post hoc test.
paclitaxel decreased cell viability to 62%. Therefore, we chose
1 µM of paclitaxel and 2 h for incubation time.
Figure 6 shows that tempol decreased the MitoSOX-detected
red fluorescence intensity at concentrations of 1 and 10 mM at 2 h
after paclitaxel treatment. These data show that tempol decreased
the mitochondrial superoxide levels in the primary DRG cell
culture.
DISCUSSION
This study investigated the therapeutic and preventive effect
of tempol in rats with PINP. Tempol produced analgesia
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FIGURE 4 | Paclitaxel increased the levels of phosphorylated protein kinase C (p-PKC), phosphorylated nuclear factor κB (p-NF-κB), PDE4D, IL-1β,
and monocyte chemoattractant protein-1 (MCP-1) in rat dorsal root ganglia (DRGs). (A) Western blot showing the expression of p-PKC, p-NF-κB, PDE4D,
IL-1β, and MCP-1 in DRGs after an injection of vehicle (VEH) or paclitaxel (PAC) on day 20. Tempol was infused for 7 days (days 14–20). (B–F) Quantification of
p-PKC, p-NF-κB, PDE4D, IL-1β, and MCP-1 in DRGs. Note that paclitaxel increased the levels of p-PKC, p-NF-κB, PDE4D, IL-1β, and MCP-1 in rat DRGs, and
tempol subsequently decreased these protein levels. The data are expressed as means ± standard deviations for three rats. The asterisks indicate values that are
significantly different (P < 0.05) from the values for the vehicle group as determined by the Mann–Whitney U test.
by inhibiting mitochondrial superoxide level, p-PKC, p-NF-
κB, PDE4D, IL-1β, and MCP-1 in DRGs. In addition, tempol
prevented the development of PINP when given during the
development phase of mechanical hyperalgesia. Therefore, the
results suggest that tempol has potential for the treatment and
prevention of chemotherapy-induced neuropathic pain.
It is well reported that oxidative stress plays an important
role in neurodegenerative diseases (Wagner et al., 1998).
Free radicals (superoxide, hydroxyl radicals, hydrogen
peroxide, and peroxynitrite) are derivatives of molecular
oxygen and nitrogen (Lander, 1997) and are produced
by both mitochondrial oxidative metabolisms and several
enzymes such as phospholipase A2, cytochrome P450,
monoamine oxidase, and tyrosine hydroxylase. In addition,
free radicals are removed by antioxidant systems including
superoxide dismutase, catalase, glutathione, and glutathione
peroxidase. Pathological condition is involved in oxidative
stress by the increased production of free radicals and/or
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FIGURE 5 | Paclitaxel increased mitochondrial superoxide levels in the
primary DRG cell culture. (A) The L1-6 DRGs were isolated from an adult
male Sprague–Dawley rat. The isolated DRG cells were plated in a chambered
coverglass in DMEM media for live cell imaging. Note that paclitaxel (1 µM)
significantly increased the MitoSOX-detected red fluorescence intensity in the
primary DRG cell cultures. The data are expressed as means ± standard
deviations for three independent experiments. The asterisks indicate values
that are significantly different (P < 0.05) from the values before treatment with
paclitaxel as determined by the unpaired t-test. (B–E) The MitoSOX-detected
red fluorescence intensity was measured in live cell imaging before (B) and 1
(C), 2 (D), and 4 h (E) after treatment with paclitaxel (1 µM). Scale bars:
20 µm.
decreased antioxidants level (Floyd, 1999; Floyd and Hensley,
2002).
Fidanboylu et al. (2011) reported that single intraperitoneal
injection of 100 mg/kg of tempol had no analgesic effect at 1,
3, and 24 h after injection, but 250 mg/kg had analgesic effect
on established paclitaxel-induced hypersensitivity at 1 h after
injection. In addition, daily systemic injection of 100 mg/kg of
tempol for 13 days did not affect the development of paclitaxel-
induced hypersensitivity (Fidanboylu et al., 2011). We think daily
systemic injection of 100 mg/kg tempol is too low a dose for
scavenging free radicals because of the lack of analgesic effect. In
FIGURE 6 | Tempol decreased paclitaxel-induced mitochondrial
superoxide levels in the primary DRG cell culture. (A) The DRG cells
were cultured in a chambered cover glass in DMEM media for live cell
imaging. Paclitaxel (1 µM) significantly increased the MitoSOX-detected red
fluorescence intensity in the primary DRG cell cultures at 2 h. Tempol (1 and
10 mM) decreased paclitaxel-induced red fluorescence intensity. The data are
expressed as means ± standard deviations for three independent
experiments. The asterisks indicate values that are significantly different
(P < 0.05) from the values before treatment with paclitaxel as determined by
the unpaired t-test. (B) The MitoSOX-detected red fluorescence without
paclitaxel at 2 h. (C) The MitoSOX-detected red fluorescence at 2 h after
treatment with paclitaxel (1 µM). (D) The MitoSOX-detected red fluorescence
of DRG cells at 2 h after treatment with paclitaxel (1 µM) and tempol (1 mM).
(E) The MitoSOX-detected red fluorescence of DRG cells at 2 h after
treatment with paclitaxel (1 µM) and tempol (10 mM). Scale bars: 20 µm.
our study, the 100 and 200 mg/kg doses of tempol significantly
increased the mechanical threshold for only 2 h. So the prolonged
effect of tempol was induced by intraperitoneal injection at
200 mg/kg as an initial dose on 2 days and an intraperitoneal
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infusion at a rate of 10 mg/day as a maintaining dose because
of the short analgesic effect of single systemic injection. This
infusion dose produced analgesic effect without sedation.
We used a PINP model in rats because paclitaxel is a first-
line drug for breast cancer and damages the peripheral nervous
system, including nerve endings, peripheral nerves, and DRG
(Dougherty et al., 2004). Paclitaxel cannot penetrate the blood-
brain barrier and thus does not accumulate located in the central
nervous system (Cavaletti et al., 2000). However, this drug does
accumulate in DRGs (Cavaletti et al., 2000). The drug may cause
damage to the sciatic nerve, nerve endings, and DRGs during the
development of pain behavior (Peters et al., 2007b). Paclitaxel
induces several events in the DRGs including (1) accumulation
of immune cells such as macrophage and polymorphonuclear
cells; (2) an increase in calcium channel subunits in the DRG
(Matsumoto et al., 2006; Peters et al., 2007a; Xiao et al., 2007);
(3) an increase in the expression of phospholipase A2, chemokine
ligand 21b, complement components 1 and 3, and matrix
metalloproteinase 3 (Nishida et al., 2008); and (4) an increase of
inflammatory cytokines such as TNF-α, IL-1, and IL-6 (Ledeboer
et al., 2007). These events may be responsible for changes in pain
behavior.
In our study, paclitaxel increased the mitochondrial
superoxide anion level in DRG cells, and tempol subsequently
decreased the level. Superoxide anion is produced by the
electron transport system in the mitochondria and is decreased
by superoxide dismutase (Liu et al., 1996). Mitochondrial
superoxide is generated as a by-product of electron transport
chain in mitochondria. MitoSOX is a cationic derivative of
dihydroethidium and is reactive with superoxide to produce
2-hydroxyethidium that induces a fluorescence (Zielonka et al.,
2008). In our study, paclitaxel increased the superoxide anion
level in the mitochondria and then induced oxidative stress
in DRGs, which may explain the pain behavior. Superoxide
anion forms hydrogen peroxide in the presence of tempol,
which is similar to native superoxide dismutase (Reddan et al.,
1993). Further, the nitroxide structure of tempol can facilitate
metabolism of a wide range of free radicals and reactive nitrogen
species. Indeed, tempol can protect cells from superoxide anion,
and hydrogen peroxide (Reddan et al., 1992). Therefore, tempol
improved pain behavior through scavenging free radicals in the
DRGs.
Furthermore, paclitaxel increased the levels of p-PKC, p-NF-
κB, PDE4D, IL-1β, and MCP-1 in the DRGs (Figures 4A–
F). PDE4D is a subgroup of PDE4 that degrades the
phosphodiesterase bond of cAMP and terminates the action
of cAMP (Houslay and Adams, 2003). The activation of
PDE4 produces inflammatory cytokines (IL-1β) and chemokines
(MCP-1) in the immune cells (Boswell-Smith et al., 2006;
Kobayashi et al., 2007; Kubo et al., 2012). Recently, rolipram, a
selective PDE4 inhibitor, was shown to decrease pain behavior
in rat PINP models (Kim et al., 2015). Also, paclitaxel has
lipopolysaccharide-like action and then accumulates immune
cells in the DRGs (Manthey et al., 1992) and increases
intracellular calcium levels, which promote the change from PKC
to p-PKC (Peters et al., 2007b; Xiao et al., 2007). The increase in
activated PKC in the DRGs was observed after treatment with
paclitaxel in a mouse model of PINP (He and Wang, 2015). In
addition, p-NF-κB, an activated form of NF-κB, is translocated
into the nucleus and then produced various proteins including
inflammatory cytokines and chemokines such as TNF-α, IL-1β,
and MCP-1, thereby inducing pain behaviors (Deshpande et al.,
1997). In addition, paclitaxel was reported to increase the level
of TNF-α in the DRG in rats (Kim et al., 2016). In this study,
tempol reduced pain behaviors by decreasing the levels of p-PKC,
p-NF-κB, PDE4D, IL-1β, and MCP-1 in the DRGs (but not those
of TNF-α: data not shown).
Most importantly, tempol completely prevented the
development of pain behaviors when it was administered
on days 6–13 after the first injection of paclitaxel but not
when it was administered on days 0–6. We found that tempol
decreased oxidative stress, p-PKC, p-NF-κB, PDE4D, IL-1β,
and MCP-1 in the DRGs. Therefore, induction of inflammatory
cytokines/chemokines and oxidative stress may have been
involved in the development of pain behaviors during days
6–13 after the first injection of paclitaxel. We plan to further
investigate the temporal significance in studying the pathological
mechanisms of the development of chemotherapy-induced
neuropathic pain.
CONCLUSION
Our study showed that systemic administration of tempol
ameliorated and prevented neuropathic pain behavior in
a rat model of PINP by inhibiting free radicals, p-PKC,
p-NF-κB, PDE4D, IL-1β, and MCP-1 in the DRGs without
inducing sedation. We conclude that oxidative stress and
inflammatory processes are involved in both development
and maintenance of chemotherapy-induced neuropathic
pain.
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